(84 days)
Not Found
Not Found
No
The summary describes a demineralized bone matrix product used for bone void filling and does not mention any software, algorithms, or data processing that would indicate the use of AI or ML.
Yes
The device is described as "Demineralized Bone Matrix for voids or gaps" and is "indicated for treatment of surgically created osseous defects or osseous defects created from traumatic injury," which aligns with the definition of a therapeutic device as it is used to treat or manage a disease or condition (bone defects/injuries).
No
This device is a demineralized bone matrix intended for use as a bone void filler and extender in surgical procedures, not for diagnostic purposes.
No
The device description clearly states that DBX® is a Demineralized Bone Matrix available in Paste, Putty, and Mix forms, composed of cadaveric bone and sodium hyaluronate. This is a physical material, not software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that DBX® is a Demineralized Bone Matrix for filling voids or gaps in bone structures during surgery. This is a therapeutic use, not a diagnostic one.
- Device Description: The description details the composition and forms of the bone matrix material, which is consistent with a surgical implant or filler.
- Lack of Diagnostic Elements: There is no mention of the device being used to test samples from the human body (like blood, urine, tissue, etc.) to provide information about a disease or condition. The device itself is implanted into the body.
IVD devices are used in vitro (outside the body) to examine specimens from the human body to provide information for diagnosis, monitoring, or screening. DBX® is used in vivo (inside the body) for surgical repair.
N/A
Intended Use / Indications for Use
DBX® is intended for use as a Demineralized Bone Matrix for voids or gaps that are not intrinsic to the stability of the bony structure. It can be used in the:
| Putty | Mix | Paste |
|---|---|---|
| Extremities | Extremities | Extremities |
| Pelvis | Pelvis | Pelvis |
| Posterolateral Spine | Spine | |
| Cranium |
DBX® is indicated for treatment of surgically created osseous defects or osseous defects created from traumatic injury. DBX® Putty can be used as an extender in the spine with autograft. DBX® Mix may be used as a bone void filler in the spine. DBX® can be used with bone marrow.
DBX® is for single patient use only.
Product codes (comma separated list FDA assigned to the subject device)
MBP, MQV
Device Description
DBX® is intended for single patient use only. DBX® Demineralized Bone Matrix is available in three forms: Paste, Putty and Mix. DBX® products are completely resorbable. DBX® Paste and Putty are composed of cadaveric cortical bone; the DBX® Mix is composed of cadaveric corticocancellous bone. The bone granules are mixed with sodium hyaluronate (NaHy) in varying combinations to form the DBX® Putty, Paste, and Mix. DBX® Putty is available in five sizes and DBX® Paste and Mix are available in four sizes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Extremities, Pelvis, Posterolateral Spine, Spine, Cranium.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Biocompatibility of DBX® materials has been established through their long history of safe and effective clinical use, further supported by laboratory testing conducted per ISO 10993. DBX® is single-donor processed using aseptic techniques and is tested for sterility per current USP .
DBX® is osteoconductive, and has been shown to have osteoinductivity potential in an athymic mouse. Every lot of final product will be tested to ensure the osteoinductive potential of the final product. Osteoinduction assay results in the athymic mouse model should not be interpreted to predict clinical performance in human subjects.
The method for processing the DBM contained in DBX® was evaluated for its viral inactivation potential. A panel of model potential human viruses representing various virus types, sizes, shapes and genomes were evaluated. The DBM processing methods were determined to provide significant viral inactivation potential for a wide range of potential viruses.
DBX will be assayed in vivo for its osteoinductive potential. Standard testing performed in an athymic mouse must prove positive for lot release.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
0
X. 510(k) SUMMARY OF SAFTEY & EFFECTIVENESS
MAR 0 5 2007
| PROPREIETARY NAME: | DBX® Demineralized Bone Matrix |
|---|---|
| COMMON NAME: | Bone Void Filler Containing Human Demineralized |
| Bone Matrix (DBM) | |
| PROPOSED REGULATORY | |
| CLASS: | Class II |
| CLASSIFICATION | |
| IDENTIFICATION: | 21 C.F.R. §888.3045 Resorbable calcium salt bone |
| void filler device | |
| PRODUCT CODE: | MBP, MQV |
| PANEL CODE: | 87—Orthopedic Devices |
| SPONSOR: | Musculoskeletal Transplant Foundation |
| 125 May Street | |
| Edison, NJ 08837 | |
| 732-661-0202 | |
| 723-661-2189 fax |
INDICATIONS FOR USE:
DBX® is intended for use as a Demineralized Bone Matrix for voids or gaps that are not intrinsic to the stability of the bony structure. It can be used in the:
| Putty | Mix | Paste |
|---|---|---|
| Extremities | Extremities | Extremities |
| Pelvis | Pelvis | Pelvis |
| Posterolateral Spine | Spine | |
| Cranium |
DBX® is indicated for treatment of surgically created osseous defects or osseous defects created from traumatic injury. DBX® Putty can be used as an extender in the spine with autograft. DBX® Mix may be used as a bone void filler in the spine. DBX® can be used with bone marrow.
DBX® is for single patient use only.
1
DEVICE DESCRIPTION:
DBX® is intended for single patient use only. DBX® Demineralized Bone Matrix is available in three forms: Paste, Putty and Mix. DBX® products are completely resorbable. DBX® Paste and Putty are composed of cadaveric cortical bone; the DBX® Mix is composed of cadaveric corticocancellous bone. The bone granules are mixed with sodium hyaluronate (NaHy) in varying combinations to form the DBX® Putty, Paste, and Mix. DBX® Putty is available in five sizes and DBX® Paste and Mix are available in four sizes.
SAFETY AND EFFECTIVENESS INFORMATION:
Biocompatibility of DBX® materials has been established through their long history of safe and effective clinical use, further supported by laboratory testing conducted per ISO 10993. DBX® is single-donor processed using aseptic techniques and is tested for sterility per current USP .
OSTEOINDUCTIVITY POTENTIAL:
DBX® is osteoconductive, and has been shown to have osteoinductivity potential in an athymic mouse. Every lot of final product will be tested to ensure the osteoinductive potential of the final product. Osteoinduction assay results in the athymic mouse model should not be interpreted to predict clinical performance in human subjects.
VIRAL CLEARANCE AND INACTIVATION:
The method for processing the DBM contained in DBX® was evaluated for its viral inactivation potential. A panel of model potential human viruses representing various virus types, sizes, shapes and genomes were evaluated. The DBM processing methods were determined to provide significant viral inactivation potential for a wide range of potential viruses.
OSTEOINDUCTIVE POTENTIAL:
DBX will be assayed in vivo for its osteoinductive potential. Standard testing performed in an athymic mouse must prove positive for lot release.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Musculoskeletal Transplant Foundation % Ms. Nancy Bennewitz Regulatory Affairs Submission Specialist 125 May Street Edison, New Jersey 08837
MAR 0 5 2007
K063676 Re:
Trade/Device Name: DBX® Demineralized Bone Matrix Mix Regulation Number: 21 CFR 888.3045 Regulation Name: resorbable calcium salt bone void filler device Regulatory Class: Class II Product Code: MQV, MBP Dated: December 7, 2006 Received: December 11, 2006
Dear Ms. Bennewitz:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 - Ms. Nancy Bennewitz
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
for
Mark N. Melkers
lkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
IV. INDICATIONS FOR USE
K063676 510(k) Number (if known):
Device Name: DBX® Demineralized Bone Matrix
Indications for Use:
DBX® is intended for use as a Demineralized Bone Matrix for voids or gaps that are not intrinsic to the stability of the bony structure. It can be used in the:
| Putty | Mix | Paste |
|---|---|---|
| Extremities | Extremities | Extremities |
| Pelvis | Pelvis | Pelvis |
| Posterolateral Spine | Spine | |
| Cranium |
DBX® is indicated for treatment of surgically created osseous defects or osseous defects created from traumatic injury.
DBX® Putty can be used as an extender in the spine with autograft. DBX® Mix may be used as a bone void filler in the spine. DBX® can be used with bone marrow.
DBX® is for single patient use only.
Prescription Use _ X OR (Per 21 CFR 801 Subpart D)
Over-The-Counter Use _ (Per 21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED.)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | |
|---|---|
| -------------------------------------------------------- | -- |
Pellm
(Division Sign-Off) Division of General. Restorative, and Neurological Devices
1.063626 510(k) Number
Confidential